<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03215043</url>
  </required_header>
  <id_info>
    <org_study_id>SaoPSU7</org_study_id>
    <nct_id>NCT03215043</nct_id>
  </id_info>
  <brief_title>Effect of Eriocitrin Supplementation in Subjects With Intermediate Hyperglycemia</brief_title>
  <official_title>Evaluation of Metabolic Parameters in Subjects With Intermediate Hyperglycemia Supplemented With Eriocitrin: A Parallel, Double-blind, Randomized, Placebo-controlled Clinical Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Thais Cesar</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Ingredients by Nature TM</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>São Paulo State University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      First, it will be evaluated whether supplementation of eriocitrin reduces hyperglycemia and
      insulin resistance, significantly reducing the risk of diabetes. The effects of eriocitrin on
      the lipid profile, inflammatory, endothelial, hepatic and renal biomarkers will also be
      evaluated. It is expected that metabolic parameters that constitute risk factors for diabetes
      and associated chronic diseases are expected to be improved by supplementation with
      eriocitrin
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Volunteers will be invited to appear in a 12-hour fast to measure glucose levels, glycated
      hemoglobin and to perform the glucose tolerance test, in addition to an individual interview
      to confirm eligibility according to the inclusion and exclusion criteria. The collection of
      blood and the glycemic curves will be carried out next to a Laboratory of Clinical Analyzes,
      commercial, based in the city of Araraquara.

      The sample number took into account variances on glycated hemoglobin with a type I error α =
      0.05 and a type II error β = 0.2 (80% power) (Mohammad, 2015). The minimum sample size
      considering an approximately 20% dropout rate, should have 20 individuals per group.

      In order to ensure adequate nutrition for the nutritional and energetic needs of volunteers,
      an individual food plan shall be prescribed, calculated according to the DRI equations. The
      volunteer will be asked to complete the Food Record for three days at the 3rd, 5th, 7th, 9th
      and 11th week. Data analysis of energy intake, macronutrients and micronutrients will be
      performed through the DietBox® . The anthropometric measurements will be performed before the
      intervention and in the 3rd, 5th, 7th, 9th and 11th week by Nutritionist. Four samples of
      30mL of fasting blood each will be obtained before the intervention, in the 4th, 8th and 12th
      week in the Laboratory of Clinical Analyzes. The blood will be centrifuged to obtain the
      serum, which will be frozen at -80 ° C until subsequent biochemical analyzes.

      Normality and homogeneity will be evaluated by Shapiro-Wilk test and Levine tests,
      respectively. The T test will be used to compare baseline time between groups. The two-way
      repeated-measures ANOVA will be used to compare changes within and between the eriocitrin and
      control groups over the 12-week period. P significant at ≤ 0.05.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">July 2, 2017</start_date>
  <completion_date type="Anticipated">June 28, 2019</completion_date>
  <primary_completion_date type="Anticipated">October 8, 2018</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Glucose</measure>
    <time_frame>12 Weeks</time_frame>
    <description>mg/dL</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>glycated hemoglobin</measure>
    <time_frame>12 Weeks</time_frame>
    <description>percentage</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>insulin</measure>
    <time_frame>12 Weeks</time_frame>
    <description>µU/mL</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cholesterol</measure>
    <time_frame>12 Weeks</time_frame>
    <description>mg/dL</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>triglycerides</measure>
    <time_frame>12 Weeks</time_frame>
    <description>mg/dL</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>HDL-C</measure>
    <time_frame>12 Weeks</time_frame>
    <description>mg/dL</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>LDL-C</measure>
    <time_frame>12 Weeks</time_frame>
    <description>mg/dL</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>TNF-alpha</measure>
    <time_frame>12 Weeks</time_frame>
    <description>pg.mL</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Interleucina 6</measure>
    <time_frame>12 Weeks</time_frame>
    <description>pg.mL</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>c-reactive protein</measure>
    <time_frame>12 Weeks</time_frame>
    <description>mg/dL</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>aspartate aminotransferase</measure>
    <time_frame>12 Weeks</time_frame>
    <description>U/L</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>alkaline phosphatase</measure>
    <time_frame>12 Weeks</time_frame>
    <description>U/L</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Gamma-Glutamyl Transferase</measure>
    <time_frame>12 Weeks</time_frame>
    <description>U/L</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>alanine aminotransferase</measure>
    <time_frame>12 Weeks</time_frame>
    <description>U/L</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Body mass</measure>
    <time_frame>12 Weeks</time_frame>
    <description>Kg</description>
  </other_outcome>
  <other_outcome>
    <measure>fat mass</measure>
    <time_frame>12 Weeks</time_frame>
    <description>kg</description>
  </other_outcome>
  <other_outcome>
    <measure>percentage of total body fat</measure>
    <time_frame>12 Weeks</time_frame>
    <description>Percentage</description>
  </other_outcome>
  <other_outcome>
    <measure>visceral fat area</measure>
    <time_frame>12 Weeks</time_frame>
    <description>cm2</description>
  </other_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">80</enrollment>
  <condition>Pre Diabetes</condition>
  <arm_group>
    <arm_group_label>Group A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Individuals will receive a dose of 140 mg / d eriocitrin for 12 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group B</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Individuals will receive a dose of 280 mg / d eriocitrin for 12 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group C</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Individuals will receive a dose of 560 mg / d eriocitrin for 12 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group D</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Individuals will receive the placebo with corn starch excipient for 12 weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Eriocitrin</intervention_name>
    <description>The selected individuals will be randomly distributed in 4 groups through random number generator program. Group A (n = 20) will receive a dose of 140 mg / d eriocitrin; Group B (n = 20) eriocitrin 280 mg / d; The C group (n = 20) 560 mg / d eriocitrin; And group D (n = 20) will receive the placebo with corn starch excipient. All doses will be packaged in Manipulation Pharmacy, and should be of the same type, color and size. Individuals will be instructed to regularly ingest a pre-dinner capsule for 12 weeks.</description>
    <arm_group_label>Group A</arm_group_label>
    <arm_group_label>Group B</arm_group_label>
    <arm_group_label>Group C</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>The selected individuals will be randomly distributed in 4 groups through random number generator program. Group A (n = 20) will receive a dose of 140 mg / d eriocitrin; Group B (n = 20) eriocitrin 280 mg / d; The C group (n = 20) 560 mg / d eriocitrin; And group D (n = 20) will receive the placebo with corn starch excipient. All doses will be packaged in Manipulation Pharmacy, and should be of the same type, color and size. Individuals will be instructed to regularly ingest a pre-dinner capsule for 12 weeks.</description>
    <arm_group_label>Group D</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Glycemia of 6.1 to 7.0 mmol / L

          -  Glycated hemoglobin with values between 5.7 and 6.4%

        Exclusion Criteria:

          -  use of drugs, vitamins and dietary supplements, alcohol consumption (&gt; 20 g
             alcohol/d), and intense physical activity (&gt; 5 hours/week).

          -  History of cardiovascular disease, diabetes mellitus, liver or kidney disease
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>30 Years</minimum_age>
    <maximum_age>59 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Thais B Cesar, Ph.D</last_name>
    <role>Principal Investigator</role>
    <affiliation>Sao Paulo State University &quot;Julio de Mesquita Filho&quot;, Faculdade de Ciências Farmacêuticas</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Thais B Cesar, Ph.D</last_name>
    <phone>+55 16 3301-6927</phone>
    <email>tcesar@fcfar.unesp.br</email>
  </overall_contact>
  <location>
    <facility>
      <name>Sao Paulo State University &quot;Julio de Mesquita Filho&quot;, Faculdade de Ciências Farmacêuticas</name>
      <address>
        <city>Araraquara</city>
        <state>Sao Paulo</state>
        <zip>14800-903</zip>
        <country>Brazil</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Thais B Cesar, Ph.D.</last_name>
      <phone>+55 16 3301-6927</phone>
      <email>tcesar@fcfar.unesp.br</email>
    </contact>
  </location>
  <location_countries>
    <country>Brazil</country>
  </location_countries>
  <link>
    <url>http://www.who.int/diabetes/publications/Definition%20and%20diagnosis%20of%20diabetes_new.pdf</url>
    <description>WHO, 2006 - Definition and diagnosis of diabetes mellitus and intermediate hyperglycemia.</description>
  </link>
  <reference>
    <citation>Mohammad M, et al. Effects of Hesperidin Supplementation on Glycemic Control, Lipid Profile and Inflammatory Markers in Patients with Type 2 Diabetes: A Randomized Double Blind Placebo Control Clinical Trial. Research Article, Acta Biologica Indica 2015, 4(1):75-83. ISSN 2279-0160</citation>
  </reference>
  <verification_date>April 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 11, 2017</study_first_submitted>
  <study_first_submitted_qc>July 11, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">July 12, 2017</study_first_posted>
  <last_update_submitted>April 17, 2018</last_update_submitted>
  <last_update_submitted_qc>April 17, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">April 18, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>São Paulo State University</investigator_affiliation>
    <investigator_full_name>Thais Cesar</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>Eriocitrin</keyword>
  <keyword>Intermediate hyperglycemia</keyword>
  <keyword>Citrus bioflavonoids</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hyperglycemia</mesh_term>
    <mesh_term>Prediabetic State</mesh_term>
    <mesh_term>Glucose Intolerance</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
    <ipd_description>There is still no decision regarding if the individual participant data (IPD) will be available to other researchers.</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

